ARTHUR-D.-LITTLE
2.6.2020 10:02:12 CEST | Business Wire | Press release
Arthur D. Little (ADL) today announced the acquisitions of Cutter Consortium, a business technology research company based in the US, and Presans, a leading player in industrial open innovation based in France. By combining its own expertise with an existing community of independent experts, ADL expands its consulting ecosystem to establish a next-generation value proposition powered by open consulting and open problem solving.
Cutter Consortium (www.cutter.com ) helps organizations navigate digital disruption of business models and leverage emerging technologies for competitive advantage and mission success. Through its research, consulting, training, and executive education – all delivered by globally recognized thought leaders – Cutter delivers innovative solutions to its thousands of clients worldwide. Cutter’s experts have done the ground-breaking work in areas ranging from digital architectures to digital tech, enterprise agility to data analytics, and digital leadership to sustainable innovation. At the heart of its business is a membership service that gives clients valuable access to its experts and their insight.
Presans (www.presans.com ) is a leading data-driven platform dedicated to industrial open innovation and open problem solving. Thanks to cutting-edge technology based on big data and artificial intelligence, as well as a team of fellows (former research and innovation executives) with in-depth knowledge in innovation, Presans leverages a network of over 6 million experts worldwide. Presans provides a variety of high-end open innovation services, contributing to the acceleration of decision-making and removal of scientific and technological roadblocks. Presans has worked for 50+ international industrial groups and delivered more than 100 innovation projects in Europe, the US and the Middle East.
“Arthur D. Little applies an ‘open consulting’ and ‘open problem solving’ approach and brings the best global experts to every assignment to complement its internal strengths,” comments Ignacio García Alves, Chairman and CEO of Arthur D. Little . “We believe the future is open consulting. With the double acquisition of Cutter and Presans, we are able to expand our open consulting ecosystem and open problem solving capabilities, offering access to experts, premium insight and a differentiated experience for our clients, in a seamless way.”
“The Cutter team felt an instant synergy with our colleagues at ADL. We share a focus on innovation, which, in ADL’s case, goes back to its roots, and an emphasis on providing custom, leading-edge solutions. Moreover, ADL’s more than 40 offices in 30 countries has given Cutter an enhanced ability to assist its clients worldwide,” says Karen Coburn, CEO of Cutter Consortium .
“Since its inception at the École Polytechnique's start-up incubator, Presans has always engaged with the best experts in the world, mainly to help its customers solve complex technical problems,” says Albert Meige, Founder of Presans . “Presans now addresses more and more problems at the crossroads of strategy consulting and scientific & technical expertise. The time had therefore come for Presans to strengthen itself by joining forces with Arthur D Little.”
Together with Cutter and Presans, ADL reinforces its position on digital and information technologies, as well as industrial innovation, particularly in breakthrough innovation and convergence problem solving. In addition, through the acquisition of the technological platform of Presans, ADL is accelerating its investments in artificial intelligence and machine learning to develop state-of-the-art offerings for its clients.
Cutter Consortium and Presans will continue to operate under their current brands with the same management teams, while benefiting from ADL’s capabilities, investment, and global exposure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom